论文部分内容阅读
目的探讨分析非甾体类消炎药在治疗风湿性疾病中的疗效和安全性。方法随机抽取2010年1月-2010年12月我院收治的80例类风湿性关节炎患者,分为观察组和对照组,每组各40例,观察组采用美洛昔康治疗,剂量为15mg/d,对照组采用布洛芬缓解胶囊治疗,剂量为600mg/d,疗程均为4周,观察和记录治疗前后两组患者在临床指标、炎性实验指标和不良反应的变化。结果治疗后观察组和对照组在关节疼痛指数、关节肿胀指数、握力、晨僵、血沉等方面均有明显好转,观察组的总有效率为89.5%,对照组的总有效率71.3%,观察组的治疗效果优于对照组(P<0.05),观察组出现胃肠道不适2例、头晕1例,对照组出现胃肠道不畅适7例、头晕2例,不良反应分别为7.5%和22.5%,差异显著(P<0.05)。结论美洛昔康和布洛芬缓解胶囊均是安全、有效的治疗类风湿性关节炎的药物,但美洛昔康是对RA关节炎性疾病则更有效、安全,值得临床推广使用。
Objective To investigate the efficacy and safety of nonsteroidal anti-inflammatory drugs in the treatment of rheumatic diseases. Methods 80 patients with rheumatoid arthritis admitted to our hospital from January 2010 to December 2010 were randomly divided into observation group and control group, 40 cases in each group. The observation group was treated with meloxicam at a dose of 15mg / d, the control group with ibuprofen remission capsule treatment, a dose of 600mg / d, the course of treatment were 4 weeks, before and after treatment in both groups were observed in clinical indicators, inflammatory changes in experimental indicators and adverse reactions. Results After treatment, the observation group and the control group showed significant improvement in joint pain index, joint swelling index, grip strength, morning stiffness and erythrocyte sedimentation rate. The total effective rate was 89.5% in the observation group and 71.3% in the control group. The observation group The treatment group was superior to the control group (P <0.05). In the observation group, gastrointestinal discomfort was found in 2 cases and dizziness in 1 case. In the control group, 7 cases were found with gastrointestinal unpleasantness and 2 cases with dizziness. The adverse reactions were 7.5% And 22.5% respectively (P <0.05). Conclusions Both meloxicam and ibuprofen remission capsules are safe and effective drugs for the treatment of rheumatoid arthritis. However, meloxicam is more effective and safe for RA arthritic diseases and is worthy of clinical promotion.